Clinical Research Papers:

A phase II prospective study of the “Sandwich” protocol, L-asparaginase, cisplatin, dexamethasone and etoposide chemotherapy combined with concurrent radiation and cisplatin, in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma

Ming Jiang, Li Zhang, Li Xie, Hong Zhang, Yu Jiang, Wei-Ping Liu, Wen-Yan Zhang, Rong Tian, Yao-Tiao Deng, Sha Zhao and Li-Qun Zou _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:50155-50163. https://doi.org/10.18632/oncotarget.16334

Metrics: PDF 1691 views  |   HTML 2529 views  |   ?  


Ming Jiang1,* Li Zhang1,4,*, Li Xie2,*, Hong Zhang2, Yu Jiang1, Wei-Ping Liu3, Wen-Yan Zhang3, Rong Tian5, Yao-Tiao Deng1, Sha Zhao3 and Li-Qun Zou1

1 Department of Medical Oncology, State Key Laboratory, Cancer Center, West China Hospital of Sichuan University, Chengdu, China

2 Radiation Oncology of Cancer Center, West China Hospital of Sichuan University, Chengdu, China

3 Pathology Department, West China Hospital of Sichuan University, Chengdu, China

4 Department of Oncology, Dujiangyan Medical Center, Dujiangyan, Sichuan, China

5 Department of Nuclear Medicine, West China Hospital of Sichuan University, Chengdu, China

* These authors have contributed equally to this work

Correspondence to:

Li-qun Zou, email:

Keywords: nasal-type, extranodal NK/T cell lymphoma, L-asparaginase, cisplatin, etoposide and dexamethasone (LVDP)

Received: June 19, 2016 Accepted: January 27, 2017 Published: March 17, 2017


Nasal-type, extranodal NK/T cell lymphoma (ENKTCL) is a special type of lymphomas with geographic and racial specificity. Up to now, the standard first-line treatment is still not unified. In our previous report, the “sandwich” protocol produced good results. Continuing to use the “sandwich” mode, a new chemotherapy composed of L-asparaginase, cisplatin, etoposide and dexamethasone (LVDP) plus concurrent chemoradiotherapy (CCRT) was conducted in more patients with newly diagnosed, I/II stage ENKTCL. The results showed that 66 patients were enrolled. Overall response rate was 86.4% including 83.3% complete response and 3.0% partial remission. With the median follow-up of 23.5 months, 3-year overall survival and 3-year progression-free survival were 70.1% and 67.4%, respectively. The survival rate in stage II and extra-cavity stage I was significantly less than that in limited stage I (p < 0.05). Therefore, we thought that the “sandwich” mode was worthy of being generalized and LVDP combined with CCRT was an effective protocol for I/II stage ENKTCL. But this regimen was not suitable for all stage I/II patients and warrants larger sample and layering investigation. This study was a registered clinical trial with number ChiCTR-TNC-12002353.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 16334